What if the shot that quiets your snack cravings also quiets the urge to click “buy now”? Weight-loss drugs may do more than shrink waistlines, and a new brain-scan study could show whether GLP-1 spending habits differ from everyone else’s. Your grocery bill is only the start.
Researchers at the Wharton School are planning a study of about 180 people, according to Scripps News. Participants will have their brains scanned while they make choices involving food and money. The goal is to see whether drugs like Ozempic and Wegovy curb impulses tied to shopping, gambling and other financial decisions.
One caveat up front: this study has not been completed. There are no results yet, and the headline question is still open. I could not find a start date, a funding source or a timeline for findings.
What Wharton Wants to Know About GLP-1 Spending Behavior
The researchers want to learn whether GLP-1 use changes the brain’s reward system. In particular, they are asking whether it weakens the pull of instant gratification. CBS News calls it a first-of-its-kind study, one that will look at whether the drugs suppress temptations like luxury purchases and gambling. In other words, it is the first serious attempt to test Ozempic impulse buying in a lab.
Michael Platt, a neuroscientist and professor at Wharton, told CBS the team expects lasting effects. “We believe GLP-1s will ultimately lead to some structural remodeling of the brain,” he said, “which is where some of those long-term impacts on food choice could show up, but also on financial decision-making.”
He also sees a possible upside for your bank account. “It might be very good financially for the average person,” Platt said, “maybe they’re putting more money into savings.”
Why Weight-Loss Drug Spending Matters to Your Wallet
Here’s the thing: millions of people are already on these drugs. Scripps reports that about 1 in 5 American adults say they have tried a GLP-1 medication. Other trackers measure it differently. Bain puts the share who have tried one at about 15%, with 7% currently taking one. The numbers don’t match because they count different things.
We already have some evidence on the spending side. A Cornell study of about 150,000 households, published in the Journal of Marketing Research, found that households with a GLP-1 user cut grocery spending by 5.3% within six months. For higher-income households, the drop topped 8%. Fast-food and coffee-shop spending fell about 8%.
Those numbers come from receipts, though, not brain scans. They show what people buy, not why.
That’s the gap the Wharton team hopes to fill. The drugs themselves keep changing, too. Lilly’s retatrutide trial hints at even stronger weight-loss drugs ahead, which could make any spending effect larger.
Where the Money Goes Instead
Spending doesn’t vanish. It moves. Numerator’s tracker shows 22% of households now include a current GLP-1 user, double the share from October 2023. After a year, those households spend about 4% less on groceries than similar households without a user. They spend more on self-care and appearance items. That shift is the clearest sign of changing GLP-1 shopping habits so far.
A BCG survey of more than 1,500 users offers a hint of what comes next. Users expect roughly one-third of the freed-up money to go to savings and another third to GLP-1 co-pays. The last third would go to supplements, beauty, apparel and fitness.
So who wins and loses? Snack makers and fast-food chains are on the losing side. Gyms, skincare brands and, well, pharmacies look better placed.
Don’t Get Ahead of the Science on GLP-1 Spending Habits
A scan can show what lights up a brain. It can’t prove that a pill makes you a better saver. Earlier research also suggests the grocery effect fades: spending largely returned to baseline after users stopped the drug. Safety questions also linger, such as South Korea’s first suspected vision-loss case tied to Wegovy-type drugs.
Access is also shifting. Massachusetts regulators report a 52% drop in commercially insured GLP-1 use for weight loss between 2025 and the first quarter of 2026, after insurers dropped coverage. That is one state’s data, but it shows the user base won’t grow in a straight line.
As for results from the Wharton team, there is no date yet. The next hard data point is likely Numerator’s quarterly tracker, expected around early November. Until then, the real question is a simple one: if a shot can quiet the urge to snack, can it quiet the urge to splurge too?
